Showing 1,141 - 1,160 results of 5,125 for search '"diffusion"', query time: 0.07s Refine Results
  1. 1141

    Is first-line treatment with polatuzumab vedotin–rituximab–cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China?... by Lin Yang, Ting Chen, Qiuling Zhao, Liangliang Dong, Wanfu Zhong, Wenbin Liu, Xiuliang Qiu, Ruyi Huang, Shengqiang Huang, Ruixiang Xie

    Published 2025-01-01
    “…Objective To evaluate the cost-effectiveness of polatuzumab vedotin–rituximab–cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) in CD20-positive patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in China.Design A Markov model was constructed to analyse the cost-effectiveness of two strategies in CD20-positive patients with previously untreated DLBCL over a lifetime horizon: (1) pola-R-CHP and (2) rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). …”
    Get full text
    Article
  2. 1142
  3. 1143
  4. 1144
  5. 1145
  6. 1146
  7. 1147
  8. 1148
  9. 1149
  10. 1150
  11. 1151
  12. 1152
  13. 1153
  14. 1154
  15. 1155
  16. 1156
  17. 1157
  18. 1158
  19. 1159
  20. 1160